Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Large Cap
Health Score : 7.62Cipla Ltd. demonstrates a strong overall financial profile, characterized by outstanding profitability and an exceptionally stable, low-debt structure. The company's ability to generate profit from its sales and assets is a significant strength. Its reliance on owner's funds rather than borrowed money indicates a very low-risk financial position, providing a solid foundation for its operations. However, a key area of concern is the company's operational efficiency. It faces challenges in quickly converting inventory into sales and collecting payments from customers. While growth has been impressive in recent years, financial projections indicate a potential slowdown and even a decline in profits, which represents a notable future risk. Despite this, the company's capacity to cover its interest payments and dividends remains excellent, underscoring its financial stability.
Health Score : 7.62Cipla Ltd. demonstrates a strong overall financial profile, characterized by outstanding profitability and an exceptionally stable, low-debt structure. The company's ability to generate profit from its sales and assets is a significant strength. Its reliance on owner's funds rather than borrowed money indicates a very low-risk financial position, providing a solid foundation for its operations. However, a key area of concern is the company's operational efficiency. It faces challenges in quickly converting inventory into sales and collecting payments from customers. While growth has been impressive in recent years, financial projections indicate a potential slowdown and even a decline in profits, which represents a notable future risk. Despite this, the company's capacity to cover its interest payments and dividends remains excellent, underscoring its financial stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
32.70
Industry Median
30.91
Large Cap Median
32.45
P/E RATIO
29.63
P/B RATIO
3.34
Industry Median
3.69
Large Cap Median
4.94
P/S RATIO
4.08
Industry Median
3.74
Large Cap Median
6.08
Others
PEG RATIO
2.58
EV/EBITDA RATIO
17.59
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1423 as on Sep 1, 2026.
Growth Score : 7.80The company's growth profile is strong but shows signs of future volatility. It has demonstrated excellent growth in revenue, earnings per share, and its asset base in recent years. This points to successful expansion and market performance. However, a significant negative projection for operating profit and net income growth in the near future is a major concern. This suggests that while the company has been expanding, its profitability from this growth is expected to decline sharply, posing a risk to future shareholder returns.
Revenue Growth RateWeakOperating Profit Growth RateAverage
Earnings Per Share (EPS) GrowthExcellentAsset Growth RateGoodNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 13.59 | 4.55 | 13.28 | 6.88 | 2.23 |
| Operating Profit Growth Rate | 7.08 | 10.41 | 25.14 | 13.3 | -17.47 |
| Earnings Per Share (EPS) Growth | 4.59 | 11.29 | 47.08 | 27.87 | -26.44 |
| Asset Growth Rate | 8.05 | 9.1 | 11.03 | 14.76 | 13.83 |
| Net Income Growth Rate | 6.61 | 11.23 | 46.63 | 26.84 | -26.7 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | ABBOTINDIA | 8.68 | 35.78 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | ALKEM | 8.08 | 27.53 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 3 | DIVISLAB | 7.91 | 94.75 | Highly Overvalued | 3441.00 | 98.20 | 2568.00 |
| 4 | LUPIN | 7.84 | 18.46 | Neutral | 8816.00 | 139.24 | 5355.00 |
| 5 | CIPLA | 7.62 | 29.63 | Neutral | 5883.00 | 43.51 | 3862.00 |
| 6 | MANKIND | 7.61 | 50.85 | Overvalued | 3617.00 | 49.34 | 1938.00 |
| 7 | ZYDUSLIFE | 7.60 | 23.31 | Neutral | 8475.00 | 35.69 | 5124.00 |
| 8 | LAURUSLABS | 7.10 | 113.10 | Neutral | 1778.00 | 13.71 | 890.00 |
| 9 | DRREDDY | 6.68 | 23.29 | Neutral | 6454.00 | 38.57 | 4158.00 |
| 10 | GLENMARK | 6.36 | 51.19 | Neutral | 4572.00 | -7.12 | 1362.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Quarterly Report⬤23rd Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
Concall Report⬤30th Oct 25
Q2 FY26 Earnings Conference Call
BULLISH SENTIMENT
Cipla Ltd. is a global pharmaceutical company focused on developing and producing affordable, high-quality medicines. It operates across therapeutic areas like respiratory, anti-infectives, cardiology, and oncology, with a significant presence in India, North America, and emerging markets. A leader in generics and complex drug products, Cipla is committed to patient access and healthcare innovation.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Cipla Ltd's P/E ratio (TTM) is 32.70, compared to the industry median of 30.91 and large cap median of 32.45.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Cipla Ltd's P/B ratio is 3.34, compared to the industry median of 3.69 and large cap median of 4.94.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Cipla Ltd's P/S ratio is 4.08, compared to the industry median of 3.74 and large cap median of 6.08.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Cipla Ltd's PEG ratio is 2.58.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Cipla Ltd's EV/EBITDA ratio is 17.59.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Cipla Ltd's ROE is 11.22%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Cipla Ltd's ROA is 13.84%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Cipla Ltd's ROCE is 17%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Cipla Ltd's operating margin is 20.89%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Cipla Ltd's net margin is 13.71%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Cipla Ltd's current ratio is 2.61.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Cipla Ltd's debt-to-equity ratio is 0.01.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Cipla Ltd's interest coverage ratio is 97.74.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Cipla Ltd's DPS is ₹12.97.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Cipla Ltd's EPS is -26.44.
(Source line: "Ratios as of 21 Sept 2026, based on last traded price of ₹1423. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1935 (as The Chemical, Industrial & Pharmaceutical Laboratories)
Headquarters: Mumbai, Maharashtra
Core Offerings: Respiratory products, Anti-infectives, Cardiology medicines, Oncology drugs, CNS therapies
Stock Listing: NSE (CIPLA), BSE (500087)
Promoter: Hamied family
1935: Founded by Dr. K.A. Hamied in Mumbai. 1937: Began manufacturing pharmaceutical products. 1960s-1970s: Focused on self-reliance in drug manufacturing and pioneered anti-asthmatic and API production. 1990s: Expanded international presence, becoming a major global generic player, notably for HIV/AIDS drugs. 2000s onwards: Accelerated growth in regulated markets (US, Europe) through strategic acquisitions and a focus on complex generics and biologics. Present Day: A leading global pharmaceutical company with a diverse product portfolio.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| India Business | 41% | Operating Profit |
| North America | 26% | Operating Profit |
| South Africa, Sub-Saharan Africa and Global Access | 19% | Operating Profit |
| Rest of World (Europe, etc.) | 14% | Operating Profit |
India Business: Encompasses branded prescription products across chronic therapies (respiratory, cardiology, diabetes, CNS) and acute therapies (anti-infectives), alongside a strong presence in consumer health (OTC) with an extensive sales and distribution network.
North America Business: Focuses on generic prescription products, including complex generics, niche products, and respiratory portfolio (e.g., nebulizers, metered-dose inhalers), leveraging its strong R&D capabilities for limited competition opportunities.
South Africa, Sub-Saharan Africa and Global Access: Cipla is a leading pharmaceutical player in South Africa across prescription, OTC, and biosimilars. It also serves other Sub-Saharan African markets and participates in global humanitarian access programs for critical diseases like HIV/AIDS.
Dr. Yusuf K. Hamied: Non-Executive Chairman. A globally recognized scientist and philanthropist, he played a pivotal role in making essential medicines, particularly for HIV/AIDS, accessible and affordable worldwide. Umang Vohra: Managing Director & Global CEO. Leads Cipla's strategic direction and global operations, focusing on sustainable growth, market expansion, and driving innovation across key markets.
Cipla USA, Inc. (USA)
Cipla (EU) Limited (UK)
Cipla Medpro (Proprietary) Limited (South Africa)
Invagen Pharmaceuticals Inc. (USA)
Exelan Pharmaceuticals Inc. (USA)
Actor Pharma (Proprietary) Limited (South Africa)
Acquisition of Actor Pharma (Pty) Limited in South Africa (completed January 2024) to expand its OTC portfolio. Recommended a final dividend of ₹8.50 per equity share for FY23.
The Cipla Ltd share price today is ₹1423 on NSE (CIPLA), as of 21 Sept 2026.
As of 21 Sept 2026, Cipla Ltd share price is ₹1423, with previous close ₹1423. Today's range is ₹1423 to ₹1423. The 52-week range is ₹1165.70 to ₹1539.70.
As of today, Cipla Ltd's market cap is ₹1,14,978.4 crore (Large Cap).
Cipla Ltd's current P/E ratio is 32.70, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 39.
Cipla Ltd's current P/B ratio is 3.34.
Cipla Ltd's current dividend yield is 0.91%. Last dividend of ₹8.50 per share was declared on 04-Aug-2023.
Cipla Ltd's EPS (TTM) is ₹-26.44.
Cipla Ltd. is a global pharmaceutical company focused on developing and producing affordable, high-quality medicines. It operates across therapeutic areas like respiratory, anti-infectives, cardiology, and oncology, with a significant presence in India, North America, and emerging markets. A leader in generics and complex drug products, Cipla is committed to patient access and healthcare innovation.
Cipla Ltd is promoted by Hamied family, holding 29.21% as of 21 Sept 2026.
Cipla Ltd is listed on NSE (CIPLA) and BSE (500087). Its next quarterly results are expected on July/August 2024 (Q1 FY25).
Capital Expenditures (CapEx)
